| Name | AZD4573 |
| Description | AZD4573 is an effective and selective CDK9 inhibitor (IC50: <4 nM). It enables transient target engagement for the treatment of hematologic malignancies. |
| In vitro | Short-term administration of AZD4573 induced a swift, dose- and time-dependent reduction in cellular pSer2-RNAPII levels, which in turn activated caspase 3, leading to apoptosis across a wide spectrum of hematological cancer cell lines. Notably, caspase activation exhibited an EC50 of 13.7 nM in the acute myeloid leukemia model MV4-11. |
| In vivo | AZD4573 demonstrates a short half-life (<1 hour) in multiple species (dog, rat, monkey) and possesses good solubility for intravenous administration. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (9.3 mM), Sonication is recommended. DMSO : 118.75 mg/mL (276.2 mM), Sonication is recommended.
|
| Keywords | Inhibitor | inhibit | Cyclin dependent kinase | CDK9 | CDK | AZD-4573 | AZD4573 | AZD 4573 |
| Inhibitors Related | Ribociclib | (E)-β-Farnesene | Amantadine | 2-Chloropyrazine | Kojic acid | Abemaciclib | 2,4,6-Trihydroxybenzoic acid | Palbociclib | Abemaciclib methanesulfonate | Sodium Oxamate | Seliciclib | Dinaciclib |
| Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |